Literature DB >> 30094614

[Pulmonary fibrosis in rheumatic diseases].

D Grund1, E Siegert2.   

Abstract

Rheumatic diseases are frequently complicated by secondary pulmonary diseases, which often impair the quality of life and increase the mortality of patients. A correct classification of such pulmonary complications is important to ensure appropriate treatment and optimal prognosis. The diagnostic and therapeutic challenge is to find the precise diagnosis and appropriate therapy among the multitude of potential causes for respiratory symptoms. It is important to maintain a cautious approach to invasive diagnostics, even though the differential diagnostics of infections or toxic lung disease might be crucial. The situation is further complicated by the frequent lack of evidence for therapies. Especially in the case of pulmonary fibrosis which is comparable to cancer in its complexity and high mortality, the diagnostics and therapy should be discussed in appropriate interdisciplinary boards.

Entities:  

Keywords:  Histology; Imaging; Immunosuppression; Interstitial lung disease; Therapy

Mesh:

Year:  2018        PMID: 30094614     DOI: 10.1007/s00108-018-0480-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Stage IV sarcoidosis: comparison of survival with the general population and causes of death.

Authors:  A Nardi; P-Y Brillet; P Letoumelin; F Girard; M Brauner; Y Uzunhan; J-M Naccache; D Valeyre; H Nunes
Journal:  Eur Respir J       Date:  2011-11-10       Impact factor: 16.671

3.  Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.

Authors:  Yossra A Suliman; Rucsandra Dobrota; Dörte Huscher; Thi D L Nguyen-Kim; Britta Maurer; Suzana Jordan; Rudolf Speich; Thomas Frauenfelder; Oliver Distler
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

Review 4.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

5.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

Authors:  E J Kim; B M Elicker; F Maldonado; W R Webb; J H Ryu; J H Van Uden; J S Lee; T E King; H R Collard
Journal:  Eur Respir J       Date:  2009-12-08       Impact factor: 16.671

6.  Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Authors:  Dinesh Khanna; Christopher P Denton; Angelika Jahreis; Jacob M van Laar; Tracy M Frech; Marina E Anderson; Murray Baron; Lorinda Chung; Gerhard Fierlbeck; Santhanam Lakshminarayanan; Yannick Allanore; Janet E Pope; Gabriela Riemekasten; Virginia Steen; Ulf Müller-Ladner; Robert Lafyatis; Giuseppina Stifano; Helen Spotswood; Haiyin Chen-Harris; Sebastian Dziadek; Alyssa Morimoto; Thierry Sornasse; Jeffrey Siegel; Daniel E Furst
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

7.  Thoracic manifestations of collagen vascular diseases.

Authors:  Julia Capobianco; Alexandre Grimberg; Bruna M Thompson; Viviane B Antunes; Dany Jasinowodolinski; Gustavo S P Meirelles
Journal:  Radiographics       Date:  2012 Jan-Feb       Impact factor: 5.333

Review 8.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

Review 9.  Sarcoidosis.

Authors:  Dominique Valeyre; Antje Prasse; Hilario Nunes; Yurdagul Uzunhan; Pierre-Yves Brillet; Joachim Müller-Quernheim
Journal:  Lancet       Date:  2013-10-01       Impact factor: 79.321

10.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.